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As part of the Cancer Drug Discovery and Development series, this
book aims to explain basic biological processes and signalling
pathways and to link that knowledge to the anticancer drugs
associated with those pathways. Each chapter begins with a
detailed introduction to the basic science of the specific process,
pathway or drug family before entering into their clinical
applications. The book is divided into six parts and, although
not officially stated, these roughly divide into two halves. The first
half deals with the mechanisms of apoptosis and other modes
of cell death; telomeres and senescence; and the DNA damage
response. In addition to apoptosis, other modes of cell
death dealt with within this half of the book include alternative
cancer therapy targets such as autophagy, anoikis and mitotic
catastrophe. The clinical aspects of the earlier chapters nicely links
to the second half of the book, which is more pharmacologically/
therapeutically orientated with three parts dealing with tumour
resistance and sensitisation, established cancer therapies and
developing cancer therapies. A flavour of the chapters in this half
of the book include, ‘perturbation of cellular functions by
Topoisomerase II inhibitors’ and ‘monoclonal antibodies in
lymphomas’. With some 28 chapters, the book covers a wide
range of topics within the title’s remit, from information on the
mechanisms of apoptosis to antimetabolite and tyrosine kinase
inhibitor therapies.
The book is generally well written and extremely informative.
The information within is as up to date as can be expected from
this kind of book, but the reader should bear in mind the speed at
which these fields are rapidly developing. The book engagingly
details the history of each area and the main studies involved in
forming that history. This gives the reader a broad understanding
of the background to the particular area of research or therapy
being discussed. On the whole, chapters are well referenced and
provide easy access to the relevant literature for further reading.
My only disappointment in the book was the under-representation
of senescence: only a couple of the 28 chapters are wholly
concerned with senescence and there are limited references to
senescence in additional chapters.
I have certainly learnt a lot from reading this book. Having been
previously solely involved in basic research, I have now moved
into a translation research cancer centre. I therefore found the
information on the therapeutic applications of what I had
previously studied in terms of cell/organism function very useful.
At d104 perhaps this book might be a little too expensive for an
individual’s collection, but I would have no hesitation in
recommending it to a laboratory/clinical group or library for
purchase.
A Young
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